|
JPH10130258A
(ja)
*
|
1996-10-10 |
1998-05-19 |
Eli Lilly & Co |
ベンゾ［ｂ］チオフェン化合物、中間体、製剤、および方法
|
|
JP2002514217A
(ja)
|
1997-04-30 |
2002-05-14 |
イーライ・リリー・アンド・カンパニー |
抗血栓物質
|
|
EP1027051B1
(en)
|
1997-04-30 |
2005-01-05 |
Eli Lilly And Company |
Antithrombotic agents
|
|
CA2287980A1
(en)
|
1997-04-30 |
1998-11-05 |
Daniel Jon Sall |
Antithrombotic agents
|
|
EP0980366B1
(en)
*
|
1997-04-30 |
2004-06-09 |
Eli Lilly And Company |
Antithrombotic agents
|
|
JP2002513415A
(ja)
|
1997-04-30 |
2002-05-08 |
イーライ・リリー・アンド・カンパニー |
抗血栓剤
|
|
AU7270798A
(en)
|
1997-05-01 |
1998-11-24 |
Eli Lilly And Company |
Antithrombotic agents
|
|
AU7550398A
(en)
*
|
1997-06-05 |
1998-12-21 |
Takeda Chemical Industries Ltd. |
Heterocyclic compounds, their production and use
|
|
US6017914A
(en)
*
|
1997-09-03 |
2000-01-25 |
Eli Lilly And Company |
Benzo[b]thiophene compounds, intermediates, formulations, and methods
|
|
US6284756B1
(en)
|
1998-04-30 |
2001-09-04 |
Eli Lilly And Company |
Antithrombotic agents
|
|
US6166069A
(en)
*
|
1998-05-12 |
2000-12-26 |
American Home Products Corporation |
Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
|
|
EP0997460B1
(en)
*
|
1998-10-28 |
2002-12-11 |
Eli Lilly And Company |
Benzothiophene compounds as antithrombotic agents and intermediates
|
|
ES2213984T3
(es)
|
1998-10-30 |
2004-09-01 |
Eli Lilly And Company |
Derivados de azaindol y su uso como agentes antitrombicos.
|
|
ATE259802T1
(de)
*
|
1999-11-19 |
2004-03-15 |
Lilly Co Eli |
Verbindungen mit antithrombotischer wirkung
|
|
WO2002094788A1
(en)
|
2001-05-22 |
2002-11-28 |
Eli Lilly And Company |
2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
|
|
DE60202954T2
(de)
|
2001-05-22 |
2006-01-05 |
Eli Lilly And Co., Indianapolis |
Tetrahydrochinolin-derivate zur behandlung von krankheiten ausgelöst durch zu hohem oder zu niedrigem oestrogenspiegel
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
JP5082033B2
(ja)
|
2001-12-21 |
2012-11-28 |
エグゼリクシス パテント カンパニー エルエルシー |
Ｌｘｒのモジュレーター
|
|
CA2490580C
(en)
*
|
2002-07-22 |
2012-12-11 |
Eli Lilly And Company |
Selective estrogen receptor modulators containing a naphthalene group
|
|
WO2005011751A2
(en)
*
|
2003-07-31 |
2005-02-10 |
University Of Pittsburgh |
Measuring device and method of measuring
|
|
US8785403B2
(en)
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
|
SI1651658T2
(sl)
|
2003-08-01 |
2020-12-31 |
Mitsubishi Tanabe Pharma Corporation |
Nove spojine, ki imajo inhibitorno aktivnost proti transporterju, ki je odvisen od natrija
|
|
WO2006084338A1
(en)
|
2005-02-14 |
2006-08-17 |
Bionomics Limited |
Novel tubulin polymerisation inhibitors
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
UY30730A1
(es)
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
|
PL2200606T3
(pl)
|
2007-09-10 |
2018-08-31 |
Janssen Pharmaceutica, N.V. |
Sposób wytwarzania związków użytecznych jako inhibitory SGLT2
|
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
|
WO2011047113A1
(en)
|
2009-10-14 |
2011-04-21 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt2
|
|
HRP20161231T1
(hr)
|
2010-05-11 |
2016-11-04 |
Janssen Pharmaceutica N.V. |
Farmaceutske formulacije koje sadrže derivate 1-(beta-d-glukopiranozil)-2-tienilmetilbenzena kao sglt inhibitore
|
|
EP2697218B1
(en)
|
2011-04-13 |
2016-05-25 |
Janssen Pharmaceutica NV |
Process for the preparation of compounds useful as inhibitors of sglt2
|
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
|
|
EP2791143B1
(en)
|
2011-12-15 |
2016-02-24 |
Bayer Intellectual Property GmbH |
Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment of cancer
|
|
JP6082033B2
(ja)
|
2012-02-23 |
2017-02-15 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ |
置換ベンゾチエニル−ピロロトリアジンおよびその使用
|
|
KR20170118687A
(ko)
*
|
2015-02-19 |
2017-10-25 |
제이엔씨 주식회사 |
벤조티오펜을 가지는 액정성 화합물, 액정 조성물 및 액정 표시 소자
|
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
|
HUE057838T2
(hu)
|
2016-06-07 |
2022-06-28 |
Jacobio Pharmaceuticals Co Ltd |
SHP2 inhibitorokként hasznos új heterociklusos származékok
|
|
SMT202400385T1
(it)
|
2017-03-23 |
2024-11-15 |
Jacobio Pharmaceuticals Co Ltd |
Nuovi derivati eterociclici utili come inibitori di shp2
|
|
US20210393623A1
(en)
|
2018-09-26 |
2021-12-23 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
|